Home Hematology and Oncology Chest Wall Irradiation Does Not Improve Survival in Intermediate-Risk Breast Cancer

Chest Wall Irradiation Does Not Improve Survival in Intermediate-Risk Breast Cancer

Findings seen in women with intermediate-risk, early breast cancer treated with mastectomy and adjuvant systemic therapy

By Elana Gotkine HealthDay Reporter

MONDAY, Nov. 10, 2025 (HealthDay News) — For patients with intermediate-risk, early breast cancer treated with mastectomy and adjuvant systemic therapy, chest-wall irradiation does not improve survival, according to a study published in the Nov. 6 issue of the New England Journal of Medicine.

Ian H. Kunkler, M.B., B.Chir., from the University of Edinburgh in the United Kingdom, and colleagues conducted a phase 3, randomized trial to examine the omission of chest-wall irradiation in women with intermediate-risk breast cancer that was treated with mastectomy, an axillary procedure, and systemic therapy. Patients were randomly assigned to either undergo chest-wall irradiation (40 to 50 Gy) or not (808 and 799 patients, respectively, in the intention-to-treat population). Patients were followed for a median of 9.6 years.

The researchers found that overall survival was 81.4 and 81.9 percent for chest-wall irradiation and no irradiation, respectively, according to 10-year Kaplan-Meier estimates (hazard ratio for death, 1.04; 95 percent confidence interval, 0.82 to 1.30; P = 0.80). Overall, 29 patients had a chest-wall recurrence: nine and 20 in the irradiation and no-irradiation groups, respectively (1.1 versus 2.5 percent; hazard ratio, 0.45; 95 percent confidence interval, 0.20 to 0.99). No significant between-group difference was seen in disease-free survival (76.2 and 75.5 percent for irradiation and no irradiation, respectively) or distant metastasis-free survival (78.2 and 79.2 percent, respectively).

“We hope that our results stimulate a reevaluation of the evidence base for indications for chest-wall irradiation,” the authors write. “Continuing to recommend chest-wall irradiation, in contexts in which evidence of benefit is marginal and the procedure is potentially detrimental, may divert limited resources from more effective treatments.”

Editorial (subscription or payment may be required)


Copyright © 2025 HealthDay. All rights reserved.